logo

Fibrogen Inc. (FGEN)



Trade FGEN now with
  Date
  Headline
12/6/2018 4:01:22 AM FibroGen Appoints Maykin Ho To Board Of Directors
10/1/2018 8:10:40 AM Astellas Submits NDA In Japan Of Roxadustat For Anemia Associated With Chronic Kidney Disease In Patients On Dialysis
9/12/2018 9:30:40 AM FibroGen Receives Fast Track Designation From FDA For Pamrevlumab For Treatment Of Idiopathic Pulmonary Fibrosis
6/3/2018 9:48:33 PM FibroGen Presents Results Of Pamrevlumab Treatment In Patients With Locally Advanced Unresectable Pancreatic Cancer
3/1/2018 7:21:14 AM Fibrogen: FDA Grants Fast Track Designation For Pamrevlumab For Locally Advanced Unresectable Pancreatic Cancer
6/26/2017 7:22:30 AM William Blair Reiterates FibroGen Inc. (FGEN) At Outperform
8/9/2016 10:44:35 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) Q4 16 Rev. Estimate To 25.0 M From 43.0 M
8/9/2016 10:44:21 AM RBC Capital Markets Is Cutting FibroGen Inc. (FGEN) Q3 16 Rev. Estimate To 23.0 M From 32.0 M
8/9/2016 10:44:07 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) 2017 Rev. Estimate To 162.0 M From 205.0 M
8/9/2016 10:43:28 AM RBC Capital Markets Is Cutting FibroGen Inc. (FGEN) 2016 Rev. Estimate To 165.6 M From 176.3 M
8/9/2016 10:43:13 AM RBC Capital Markets Is Cutting FibroGen Inc. (FGEN) Q4 16 Estimate To -0.73 From -0.19
8/9/2016 10:42:59 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) Q3 16 Estimate To -0.72 From -0.32
8/9/2016 10:42:48 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) 2017 Estimate To -2.30 From -0.62
8/9/2016 10:42:38 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) 2016 Estimate To -1.52 From -0.57
3/1/2016 9:06:36 AM RBC Capital Markets Is Increasing FibroGen Inc. (FGEN) 3Q16 Estimate To -0.48 From -0.49
3/1/2016 9:06:16 AM RBC Capital Markets Is Raising FibroGen Inc. (FGEN) 2017 Estimate To -0.48 From -0.49